Collaboration with SRI Provides QBioMed Expertise in Formulation Development and Preclinical Work in Autism, as well as CMC and Manufacturing capability
NEW YORK, December 12, 2018 — Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company, is pleased to announce a collaborative agreement with SRI International to provide formulation development, preclinical development, and early clinical manufacturing of QBM-001, in support of Q BioMed’s Autistic Spectrum Disorder (ASD)drug development program for non-verbal or minimally verbal autistic children.
SRI has broad expertise in solving formulation, drug delivery, and characterization challenges of small molecule drugs and biologics. The formulation team, led by Dr. Gita Shankar, is experienced in the development of novel formulations that have reached clinical trials. They are currently developing a formulation for QBM-001 with relatable chemical properties and formulation requirements.
The preclinical studies for QBM-001 will be led by Dr. Stephen Morairty and his team in SRI’s Center for Neuroscience. Dr. Morairty and his colleagues are experienced in working with several preclinical autism models.
“We are pleased to have found both experience with autism models and expertise in formulation of products like QBM-001 in SRI International,” said Denis Corin, CEO of Q BioMed Inc. “This important step will be the catalyst for several milestones for QBM-001 over the next few months as we prepare clinical product for the trials we anticipate starting in 2019.”
QBM-001 targets toddlers with pediatric developmental nonverbal disorder, where an underlying commonality may lead to developmental delay, an autism diagnosis and eventual nonverbal or very minimally verbal capability for the rest of their lives.
About Pediatric Development Nonverbal Disorder
There are approximately 18,000 new cases of pediatric developmental nonverbal disorder in the US each year and a similar amount in Europe. The majority of the children are diagnosed as young children and fall within the autism and epilepsy spectrum disorders. Individually, the economic cost for toddlers that become non- or minimally verbal is $10 Million on average per person over a life span. Collectively, an estimated $200 Billion is spent yearly on individuals who have become nonverbal in the US. Not all individuals who become nonverbal will benefit from QBM-001. However, with validated biomarkers, testing from trained specialists and genetic testing, children who fall into this targeted population can be identified, and will have a higher likelihood of responding to treatment.
SRI International creates world-changing solutions to make people safer, healthier, and more productive. SRI, a research center headquartered in Menlo Park, California, works primarily in advanced technology and systems, biosciences, computing, and education. SRI Biosciences is a well-established, trusted source for a wide array of contract services under the highest industry standards. With deep scientific resources and expertise, we take R&D from idea through the start of human clinical trials.
About Q BioMed Inc.
Q BioMed Inc., ”Q“,is a biomedical acceleration and development company. We are focused on licensing and acquiring undervalued biomedical assets in the healthcare sector.Q is dedicated to providing these target assets; strategic resources,developmental support, and expansion capital to ensure they meet their developmental potential, enabling them to provide products to patients in need. Please visit www.qbiomed.com and sign up to receive regular updates. Follow us on social media @QBioMed.
This press release may contain “forward-looking statements”within the meaning of Section 27A of the Securities Act of 1933 and Section 21Eof the Securities Exchange Act of 1934. Such statements include, but are notlimited to, any statements relating to our growth strategy and productdevelopment programs and any other statements that are not historical facts.Forward-looking statements are based on management’s current expectations andare subject to risks and uncertainties that could negatively affect ourbusiness, operating results, financial condition and stock price. Factors thatcould cause actual results to differ materially from those currentlyanticipated are: risks related to our growth strategy; risks relating to theresults of research and development activities; our ability to obtain, performunder and maintain financing and strategic agreements and relationships;uncertainties relating to preclinical and clinical testing; our dependence onthird-party suppliers; our ability to attract, integrate, and retain keypersonnel; the early stage of products under development; our need for substantialadditional funds; government regulation; patent and intellectual propertymatters; competition; as well as other risks described in our SEC filings. Weexpressly disclaim any obligation or undertaking to release publicly anyupdates or revisions to any forward-looking statements contained herein toreflect any change in our expectations or any changes in events, conditions orcircumstances on which any such statement is based, except as required by law.
Q BioMed Inc
Source: Q BioMed Inc